The Risk of Cytomegalovirus Infection in Non-myeloablative Peripheral Stem Cell Transplantation Compared with Conventional Bone Marrow Transplantation.
10.3346/jkms.2004.19.2.172
- Author:
Suk Joong OH
1
;
Kyoo Hyung LEE
;
Je Hwan LEE
;
Seong Jun CHOI
;
Woo Kun KIM
;
Jung Shin LEE
;
Mi Na KIM
Author Information
1. Department of Internal Medicine, Kangbuk Samsung Hospital, Division of Oncology-Hematology, Seoul, Korea.
- Publication Type:Original Article ; Comparative Study
- Keywords:
Cytomegalovirus;
Hematopoietic Stem Cell Transplantation;
Bone Marrow Transplantation;
Ganciclovir
- MeSH:
Adolescent;
Adult;
Antigens, Viral/blood;
Antiviral Agents/therapeutic use;
Bone Marrow Transplantation/*adverse effects/statistics & numerical data;
Comparative Study;
Cytomegalovirus Infections/*epidemiology/prevention & control;
Female;
Ganciclovir/therapeutic use;
Hematopoietic Stem Cell Transplantation/*adverse effects/statistics & numerical data;
Human;
Incidence;
Male;
Middle Aged;
Retrospective Studies;
Risk Factors;
Treatment Outcome
- From:Journal of Korean Medical Science
2004;19(2):172-176
- CountryRepublic of Korea
- Language:English
-
Abstract:
Non-myeloablative allogeneic peripheral stem cell transplantation (NST) is a novel therapeutic strategy for patients with hematologic malignancies. Whether non-myeloablative transplants are associated with increased risk of cytomegalovirus (CMV) infections is unknown. To clarify this issue, we compared the outcome of CMV infection following 24 allogeneic non-myeloablative peripheral blood stem cell transplants and 40 conventional bone marrow transplants (CBT). The NST regimen consisted of busulfan (4mg/kg/day), fludarabine (30mg/m2) and anti-thymocyte globulin (10mg/kg). Twelve patients (50%) in the NST group and 17 (43%) in the CBT group developed positive antigenemia before day 100 (p=0.60). The time to the first appearance of positive antigenemia was not different between these two groups (p=0.40), and two groups showed similar initial and maximal antigenemia values (p=0.56 and p=0.68, respectively). Only one case of CMV colitis developed in the CBT group whereas CMV disease did not develop in the NST group. Although statistically insignificant, the treatment response against CMV antigenemia using ganciclovir was in favor of NST group. In conclusion, there was no difference in the risk of CMV infection between NST group and CBT group. Further prospective and controlled study is needed to clarify the impact of non-myeloablative procedure on the outcome of CMV infection.
